Early research (Phase 1)Looking for participantsNCT07064122
What this trial is testing
AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
Who this might be right for
Haematologic Neoplasms
AstraZeneca 72